Company profile
Reverse Cell Ageing - Senisca
Senisca Ltd is a UK company with status active founded in 2020 based in South West England.
Updated 06 Jun 2026 16:52
Financial period: 1 Jan 2024 to 31 Dec 2024
Reference milestones and recent Companies House filing stream events.
Next accounts due date
Next confirmation statement due date
Last accounts made up date
Last confirmation statement made up date
CS01 | Transaction MzQzOTU0MTIzN2FkaXF6a2N4
Published 15 Oct 2024 10:23
AP01 | Transaction MzQzNzE2OTMxMWFkaXF6a2N4
Published 27 Sep 2024 12:29
AA | Transaction MzQzMTg2NTIyMGFkaXF6a2N4
Published 12 Aug 2024 14:53
Company registered at Companies House
Senisca develops technology that aims to reverse cellular senescence.
SENISCA Ltd. Spun out from University of Exeter in Oct 20. Currently at 10x FTE positions in UK with a further 0.5x FTE position embedded in labs at Murdoch University.
SENISCA Ltd. Spun out from University of Exeter in Oct 20. Currently at 10x FTE positions in UK with a further 0.5x FTE position embedded in labs at Murdoch University.
1 May 2023 to 31 Oct 2025
Here we propose a highly innovative RNA medicine project that will leverage the previous work carried out by SENISCA on the identification of a new and druggable set of target genes to enable significant senescence reversal effect in primary human cell lines. This project is a step forward towards the most innovative and fruitful avenue for novel therapeu...
1 Apr 2022 to 31 Mar 2023
At SENISCA we have discovered a new way by which cells age; loss of alternative splicing, a form of fine-tuning of gene expression. We can restore this process to 'turn back the ageing clock' in old (senescent) human cells. This presents a possible solution to many of the healthcare challenges faced by our ageing society, offering restorative, as well as ...
1 Jan 2022 to 31 Mar 2022
SENISCA is a biotech spinout company from the University of Exeter, founded in 2020 and dedicated to the development of new approaches to reverse cellular senescence (senotherapeutics). Our founders are world leaders in molecular and cellular biology and have patent-protected an innovation for the reversal of cell aging. This innovation works by restoring...
1 Mar 2021 to 31 May 2022
Ageing is a universal phenomenon and the primary risk factor for most common, chronic human diseases. Our company, SENISCA, is a spin-out from the University of Exeter, initially focussing on developing molecules suitable for treatment of skin ageing, followed by a wider vision to deliver innovative, effective pharmaceutical treatments for age-related dis...
